

PFF Summit 2025

November 13-15, 2025 Chicago, Illinois

Jointly provided by Partners for Advancing Clinical Education and the Pulmonary Fibrosis Foundation

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc., Inmed Incorporated and United Therapeutics

Instructions to Claim Credit

To receive CE credit, learners must follow these steps:

1. Visit <https://cme.partnersed.com/PFF25>
2. Select the type of credit desired
3. Enter your profile information
4. Complete the activity assessment/evaluation
5. Upon successful completion of all assessment/evaluation questions, your credit will be made available for download immediately.

For Pharmacists: Upon successfully completing the activity evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Target Audience

This activity is intended for physicians, physician's assistants, respiratory therapists, pharmacists, nurse practitioners, and registered nurses engaged in the care of patients with pulmonary fibrosis.

Educational Objectives

Upon completion of this activity, participants should be able to:

- | |
|---|
| • Explain the pathophysiology of IPF based on the most current data |
| • Accurately diagnose IPF using a systematic approach |
| • Effectively implement key diagnostic procedures including HRCT scanning and surgical lung biopsy |
| • Discuss recent evidence for treatments in the management of IPF/ILD and for those post COVID-19 |
| • Recognize genetic components of IPF |
| • Describe the role of lung transplantation in IPF, and the factors that affect candidacy and timing |
| • Provide patient lifestyle management tools which improve functional status |
| • Develop a comprehensive approach to the management of IPF/ILD, that includes both pharmacologic and non-pharmacologic therapies |
| • Provide accurate and appropriate care and counsel for patients and their families |

Faculty and Disclosure of Conflicts of Interest

Partners requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Partners policy. Partners is committed to providing learners with high-quality accredited CE

activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The **faculty** disclosures will be made at the beginning of their presentation(s) and are also available for review in the Speaker Ready Room.

The **Partners** and **PFF** planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and the Pulmonary Fibrosis Foundation (PFF). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 22.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you **MUST** pass the posttest and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through Partners Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Partners permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 22.0 contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 22.0 contact hours (.22 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number – JA4008073-9999-25-223-L01-P)

Type of Activity (select one): Knowledge

Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Social Work Continuing Education



As a Jointly Accredited Organization, Partners for Advancing Clinical Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 22.0 Clinical continuing education credits.

Continuing Respiratory Care Education

This program has been approved for 19.5 contact hours Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425, N. MacArthur Blvd, Suite 100, Irving TX 75063. **Course # 195191000.**

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.